Your take completely ignores the documented regulatory process and instead repeats unfounded speculation. The SEC filing explicitly states that the FDA provided input on the clinical trial protocol, and that exact protocol is what’s being executed in India—not some watered-down version. This includes specifications for the same device intended for eventual market approval. That’s not speculation—that’s regulatory fact.
Market Data 
Markets 
